Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) have earned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $90.25.
A number of research firms have recently weighed in on RARE. Cantor Fitzgerald initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, April 26th. They set an “overweight” rating and a $114.00 target price for the company. Citigroup cut their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 in a report on Friday, March 17th. Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, February 3rd. Robert W. Baird boosted their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Finally, StockNews.com initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Thursday, May 18th. They issued a “hold” rating for the company.
Insider Buying and Selling at Ultragenyx Pharmaceutical
In other news, CAO Theodore Alan Huizenga sold 639 shares of the company’s stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $43.40, for a total value of $27,732.60. Following the sale, the chief accounting officer now directly owns 15,558 shares of the company’s stock, valued at approximately $675,217.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Camille L. Bedrosian sold 3,881 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $45.25, for a total value of $175,615.25. Following the transaction, the executive vice president now directly owns 46,720 shares of the company’s stock, valued at $2,114,080. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Theodore Alan Huizenga sold 639 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $43.40, for a total transaction of $27,732.60. Following the completion of the sale, the chief accounting officer now owns 15,558 shares in the company, valued at approximately $675,217.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,299 shares of company stock worth $518,716. 6.70% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Price Performance
Shares of Ultragenyx Pharmaceutical stock opened at $50.71 on Friday. The business has a fifty day simple moving average of $42.16 and a two-hundred day simple moving average of $42.10. Ultragenyx Pharmaceutical has a 1 year low of $33.36 and a 1 year high of $68.68. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of -4.95 and a beta of 0.94.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.97) by ($0.36). Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative return on equity of 149.75%. The business had revenue of $100.50 million for the quarter, compared to analyst estimates of $103.90 million. During the same period in the prior year, the business earned ($2.19) EPS. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical will post -8.4 earnings per share for the current fiscal year.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.